Andere Sprachen Catalyst Pharmaceuticals, Inc.

Aktien

A0LCUL

US14888U1016

CPRX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
14,89 ^USD	+1,43 %		-1,59 %	-11,42 %

10.04.	Catalyst Pharmaceuticals Insider verkaufte Aktien im Wert von 392.000 $, laut einer aktuellen SEC Einreichung	MT
28.03.	Catalyst Pharmaceuticals Insider verkaufte Aktien im Wert von 411.000 $, laut einer aktuellen SEC Einreichung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Santhera dans les chiffres noirs en 2023	25.04.
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024	22.04.
Catalyst Pharmaceuticals Insider Sold Shares Worth $392,000, According to a Recent SEC Filing	10.04.
Certain Stock Options of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	04.04.
Certain Restricted Stock Units of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	04.04.
Certain Common Stock of Catalyst Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 4-APR-2024.	04.04.
Catalyst Pharmaceuticals Insider Sold Shares Worth $411,000, According to a Recent SEC Filing	28.03.
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day	28.03.
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium	27.03.
Santhera: lancement de l'Agamree contre la myopathie de Duchenne aux USA	14.03.
Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE(R) (Vamorolone) in the United States	14.03.
Catalyst Pharmaceuticals' Agamree Now Available in US to Treat Duchenne Muscular Dystrophy	13.03.
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)	13.03.
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)	13.03.
Catalyst Pharmaceuticals Announces Agamree® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy	13.03.
Catalyst Pharmaceuticals Receives Buy Rating From BofA on Track Record for License, Acquisition Deals	07.03.
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference	05.03.
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference	05.03.
Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024	29.02.
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	29.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

Catalyst Pharmaceuticals, Inc.: Optimistisches Szenario

Am 10. März 2023 um 15:15 Uhr